Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years

Trial Profile

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA 15 (Primary)
  • Indications Lyme disease
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer

Most Recent Events

  • 27 Feb 2019 Status changed from active, no longer recruiting to completed.
  • 31 Jan 2019 Initial booster data and final data from the study, presented in a Valneva media release.
  • 02 Aug 2018 According to a Valneva media release, based on the results of the Interim analysis, the Company amended the protocol to include a booster evaluation at one year post initial vaccination, in approximately 60 subjects. Results are expected in the first half of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top